2017 Program


High Country continues to attract and blend experts from academia and industry, with leaders in medical specialties, the regulatory agencies and health care researchers in an informal setting to facilitate dialog and an exchange of ideas. The meeting consists of six (6) hours of structured sessions per day (9 sessions total). In between sessions, there are ample opportunities for independent meetings, networking and discussions. The 2017 meeting, with anticipated attendance in excess of 100 participants, promises to open avenues and opportunities of collaboration on a variety of issues important to the nuclear medicine and molecular imaging community.


Friday, February 24, 2017

4:00 pm – 6:00 pm          Registration Open

Saturday, February 25, 2017

6:30 am – 7:00 am          Breakfast with the Vendors


7:00 am – 9:30 am
Quantitative Imaging: Role in Precision Medicine
Session Chair: James Fletcher, MD, FACR, FSNMMI & Hans Vija, PhD  

Protocols for quantitative PET/CT imaging as described by QIBA and UPICT Protocols are essential ingredients in clinical trials and also need to accompany efforts to decode/describe tumor imaging phenotypes using Radiomics. Our images are more than pretty pictures and with adoption of these endorsed criteria for quantitative oncologic imaging we can begin to develop classifier models to guide precision medicine approaches for patient care, predict outcomes (prognosis) and monitor success of therapeutic interventions.


Introduction – Genomes, Phenomes and Phenotypic Imaging
Speaker: James Fletcher, MD, FACR, FSNMMI

UPICT Protocol for 18F-FDG PET/CT Imaging in Oncology
Speaker: Michael Graham, MD, PhD, FSNMMI

Industry Perspective
Speaker: Hans Vija, PhD

Decoding Tumor Imaging Phenotypes
Speaker: James Fletcher, MD, FACR, FSNMMI

Panel Discussion


4:00 pm– 7:30 pm
Molecular Imaging of Prostate Cancer
Session Chair: Dominique Delbeke, MD, PhD & Michael Graham, MD, PhD, FSNMMI

In this session, Molecular Imaging of Prostate Carcinoma will be discussed, including imaging with 18F-Fluciclovine, 68Ga and 18F-PSMA, Bombesin, 18F-FLT, and Urokinase-type Plasminogen Activator Receptor.


68Ga-PSMA-11 Experience in the US
Speaker: Thomas Hope, MD

18F-PSMA for Evaluation of Prostate Cancer
Speaker: Steve Cho, MD

Bombesin for Evaluation of Prostate Cancer
Speaker: Andrew Stephens, MD, PhD

Imaging Cellular Proliferation in Prostate Cancer with PET
Speaker: Hossein Jadvar, MD, PhD, MPH, MBA, FACNM, FSNMMI

Urokinase-Type Plasminogen Activator Receptor (uPAR) PET
Speaker: Andreas Kjaer, MD

18F-FACBC for Evaluation of Prostate Cancer
Speaker: Jennifer Kujak, MD


Sunday, February 26, 2017

6:30 am – 7:00 am          Breakfast with the Vendors


7:00 am – 9:30 am
Neuroendocrine Tumors (NET) Theranostics
Session Chair: Andreas Kjaer, MD

Neuroendocrine tumors have for many years been the showcase of the theranostic principle in nuclear medicine. Recently, further momentum has been gained as a PET tracer for somatostatin receptor scintigraphy was FDA approved and finally a randomized, controlled phase III study was concluded on PRRT. The session on NET theranostics will give an overview of these major milestones as well as discuss what to expect in the future within NET imaging and PRRT.


NETTER-1 study: Impact for Use of 177Lu-DOTATATE PRRT.
Speaker: Jonathan R. Strosberg, MD, PhD     *Video Presentation*

New trends in PRRT: A Breif Introduction
Speaker:Michael Wissmeyer, MD, PhD

68Ga-DOTATATE: The Road to FDA Approval
Speaker: Dominique Delbeke, MD, PhD

64Cu-DOTATATE: The Isotope Matters
Speaker: Andreas Kjaer, MD, PhD

FLT-PET in NET: Any Role?
Speaker: TBA

Panel discussion


4:00 pm– 6:30 pm
The Fireside Conference: The Future of Nuclear Medicine
Session Chair: Michael Wissmeyer, MD

Not only during the last decade, the sense and the existence of nuclear medicine as a specialty of its own has repeatedly been contested by different stakeholders. Nevertheless, it persisted thanks to its innovational power and unique capability to visualize and treat diseases on a molecular level. However, the introduction hybrid imaging such as PET/CT and, more recently PET/MRI, as well as more and more important overlaps with other clinical specialties, especially endocrinology, oncology and cardiology once again puts pressure on the specialty. In this session, international experts from all over the world will discuss the situation in their respective countries and discuss proposals how this pressure could be overcome and how nuclear medicine could be positioned in order to attract young academics as well as clinicians.


Speaker: James Fletcher, MD, FACR, FSNMMI

Speaker: Robert Mansberg, MD

The Netherlands
Speaker: Roelof Bennink, MD, PhD

Speaker: Michael Wissmeyer, MD


7:00pm – 10:00pm          Networking Reception/Dinner in the Sundown Room

Monday, February 27, 2017

6:30 am – 7:00 am          Breakfast with the Vendors


7:00 am – 9:30 am
Regulatory and Legislative Developments – Nuclear Medicine’s Transition to a New Payment Paradigm

Session Co-Chairs: Robert Hendel, MD, FACC, FAHA, MASNC & Ira Goldman, MA

Major healthcare legislation passed by Congress in recent years including the Protecting Access to Medicare Act of 2014 (PAMA) and the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA) seek to improve quality and “bend” the cost curve through a transition from fee for service to alternative payment models. Central to these efforts are the development of Appropriate Use Criteria (AUC) and their practical use via Clinical Decision-Support (CDS) systems. Additionally, patient access to FDA-approved diagnostic radiopharmaceuticals (which CMS treats as “supplies”) may be negatively impacted by lack of or inadequate CMS reimbursement. NOPR and IDEAS are the most prominent recent examples of expensive and time-consuming CMS-mandated Coverage with Evidence Development (CED) registries, even after which routine CMS reimbursement is not guaranteed. This session will provide updates regarding an overview of possible upcoming regulatory changes and the nuclear medicine sector preparations for the healthcare system transition.


MACRA: Merit-based Incentive Payment Systems (MIPS), Alternative Payment Models (APMs), and the Future of Healthcare
Speaker: Allen Seals, MD, FACC

PAMA and the Concept of Provider Lead Entity, Appropriate Use Criteria (AUC) Selection, and the Development of Clinical Decision Support (CDS) Tools
Speaker: Robert Hendel, MD, FACC, FAHA, MASNC

SNMMI Actions to Implement New CMS Guidance for CDS and AUC’s
Speaker: Kevin Donohoe, MD

U.S. FDA – How to Improve the Efficiency of Clinical Trials to Achieve Regulatory Objectives in “Parallel” Opportunities and Challenges for Drug Developers Interested in Pursuing this Path
Speaker: Lou Marzella, MD, PhD

Coverage with Evidence Development (CED) Activities Including IDEAS and NOPR
Speaker: Denise A. Merlino, MBA, CPC

Panel Discussion


4:00 pm– 7:30 pm           
Unconventional Cardiac Session
Session Chair: Robert Hendel, MD, FACC, FAHA, MASNC

The session provides contemporary information about cardiac nuclear medicine, beyond standard SPECT myocardial perfusion imaging. The goal is to highlight new methods and applications in cardiac imaging and to provide a better understanding of future directions for nuclear cardiology. The program features world-renown experts who will provide concise literature updates, as well as personal reflections on the future of the field.


Cardiac Amyloidosis and Sarcoidosis
Speaker: Sharmila Dorbala, MD, MPH, FASNC

Cardiac Infections (Endocarditis, Device)
Speaker: Jean-François Sarrazin, MD, FRCPC, FACC, FHRS

Status of Clinic Cardiac PET
Speaker: Gary Heller, MD, PhD, MASNC   

Quantitative Myocardial Blood Flow
Speaker: Tim Bateman, MD

Future of Clinical Cardiac PET (Flurpiridaz)
Speaker: Jamshid Maddahi, MD, FACC, FASNC

Cardiac CT for Assessment of Ischemia: Impact on Nuclear MPI-Berman
Speaker: Daniel Berman, MD, FASNC

Panel Discussion

Tuesday, February 28, 2017

6:30 am – 7:00 am          Breakfast with the Vendors


7:00am – 9:30am
Quantitative SPECT/CT to Guide Therapy
Session Chairs: Ernie Garcia, PhD & Hans Vija, PhD 

This session will cover the emerging field of quantitative SPECT/CT image guided therapy. The related technical considerations will be presented. Emerging clinical applications made possible by this technology in 177Lu, 90Y, PSMA and other image-guided therapy applications will be presented in the context of quantitative SPECT/CT. Technical impediments that need to be overcome will be discussed.


Technical Aspects of Quantitative SPECT/CT CZT Imaging
Speaker: Gil Kovalski, PhD

Quantitative 177Lu SPECT/CT Imaging
Speaker: Jean-Mathieu Beauregard

90Y SPECT-CT Images Analysis for 3D Dosimetry
Speaker: Valeria Moncayo, MD

Quantitative SPECT/CT PSMA Targeted Imaging
Speaker: Tom Armor

The Future of Quantitative Multimodal SPECT
Speaker: Hans Vija, PhD

Panel: Moving from Qualitative to Quantitative SPECT/CT Clinical Use – Is It Time?

Technical Challenges of Y90 Tomography: Difficulties with SPECT and PET Y90 Imaging
Speaker: Karin Knesaurek, PhD


4:00 pm– 7:30 pm           
Neurodegenerative Disease Data Analysis
Session Chair: Val Lowe, MD


Non-PET Biomarkers and Quantification, MRI, CSF, Serum, DaTscan
Speaker: Kejal Kantarci, MD

Amyloid PET Quantification
Speaker: Val Lowe, MD 

Tau PET Quantification
Speaker: Michael PontecorvoPhD

FDG PET Quantification
Speaker: Dan Silverman, MD, PhD

The Impact of MRI/PET Image Registration and PET Normalization on Dementia Imaging
Speaker: Christopher G. Schwarz, PhD

BIG DATA and How it Relates to Imaging
Speaker: Andrew DeLao

Wednesday, March 1, 2017

6:30 am – 7:00 am          Breakfast with the Vendors


7:00 am – 9:30 am
Pediatrics, PET/MRI, Neuroblastoma, Brain Tumor, C-11
Session Chairs: Alan Packard, PhD & Barry Shulkin, MD, MBA

This focus of this session will be on recent developments in Pediatric Nuclear Medicine with an emphasis on imaging and therapy of neuroblastoma and other pediatric malignancies.  The session will cover new agents for imaging neuroblastoma, new radiotherapeutics and new developments in existing radiotherapeutics, and a discussion of options for imaging pediatric brain tumors.


The Latest and Greatest PET Imaging Agents for Neuroblastoma: Small Molecules vs. Labeled Peptides vs. Antibodies
Speaker: Scott Snyder, PhD

Somatostatin Receptor Imaging and Therapy in Children
Speaker: Yusuf Menda, MD

PET/MRI in Pediatric Oncology
Speaker: Miguel Pampaloni, MD, PhD

131I-mIBG Therapy: Still Important in an 177Lu World?
Speaker: Miguel Pampaloni, MD, PhD

11C-Methionine: The Optimal Agent for Pediatric Brain Tumors?
Speaker: Barry Shulkin, MD, MBA

Speakers: Alan Packard, PhD & Barry Shulkin, MD, MBA


Comments are closed.